Chengdu Ucello Biotechnology Co., Ltd.
Clinical trials sponsored by Chengdu Ucello Biotechnology Co., Ltd., explained in plain language.
-
Engineered immune cells take on lupus in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CD19/BCMA CAR-T cell therapy for adults with refractory systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. About 24 participants will receive a single infusion of their own engineered immune cells …
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests whether a patient's own immune cells, modified to target a protein called Claudin18.2, can safely treat advanced solid tumors. Eighteen adults whose cancer has not responded to standard treatments will receive the modified cells and be monitored for s…
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC